Christianne Groeneveldt

11PUBLICATIONS
70CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 31, 2026
Neutralizing the IL-12/IL-23 p40 subunit prevents immune checkpoint blockade toxicity without compromising antitumor efficacy.

|May 06, 2026
Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade.

|Nov 28, 2025
REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.

Songul Kucukcelebi, Freek R van 't Land, Sjoerd H van der Burg

|Jan 09, 2024
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.

Christianne Groeneveldt, Priscilla Kinderman, Lisa Griffioen

|Jan 03, 2024
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.

Jim Middelburg, Marjolein Sluijter, Gaby Schaap

|Dec 01, 2023
Preclinical evaluation of the gorilla-derived HAdV-B AdV-lumc007 oncolytic adenovirus 'GoraVir' for the treatment of pancreatic ductal adenocarcinoma.

Selas T F Bots, Tom J Harryvan, Christianne Groeneveldt

Pageof 2

Frequent Collaborators

6 joint publications

Thorbald van Hall

5 joint publications

Sjoerd H van der Burg

5 joint publications

Nadine van Montfoort

5 joint publications

Rob C Hoeben